Moderna Inc. today announced an agreement with the U.S. government for the purchase of an additional 200 million doses of Moderna’s COVID-19 vaccine, along with an option to purchase other COVID-19 vaccine candidates in the biotech company’s development pipeline.

The purchase will bring the total number of federally owned doses to 500 million, with delivery stretching into 2022. Moderna said the additional doses could be used for primary vaccination, including children, for which Moderna has yet to receive Food and Drug Administration approval, or as a booster for those with waning antibody protection.

Related News Articles

Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…